Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer

Stefania Mantarro, Marta Rossi, Martina Bonifazi, Roberto D’Amico, Corrado Blandizzi, Carlo La Vecchia, Eva Vanna Lorenza Negri, Pasquale Lorenzo Moja

Research output: Contribution to journalArticle

Abstract

Trastuzumab prolongs survival in women with HER2-positive breast cancer, but may increase the risk of heart disease. The occurrence of severe cardiotoxicity, however, is not defined in real-life settings. We performed a meta-analysis of clinical trials and cohort studies to estimate the frequency of cardiotoxicities following trastuzumab treatment. We searched MEDLINE, EMBASE, and the Cochrane Library (1996–January 2014). The primary outcome was the frequency of severe cardiotoxicities up to 3-years after trastuzumab initiation. Among 58 studies (29,598 patients), severe cardiotoxicity occurred in 3.00 % (95 % CI 2.41–3.64), 2.62 % (95 % CI 1.97–3.35), and 3.14 % (95 % CI 2.12–4.37) of overall, early (EBC) and metastatic (MBC) breast cancer patients, respectively. In EBC, the proportion increased from 2.40 % at the first year to a plateau of approximately 3 % after the second year. In MBC, the proportion increased from 3.00 to 3.68 % when trastuzumab was used as first line or further lines of therapy, respectively. In EBC, cardiotoxicity occurred in 2.90 % of patients treated with taxanes and anthracyclines compared to 0.92 % in patients treated with taxanes without anthracyclines. The occurrence of cardiotoxicity varied according to age, increasing from 2.31 % in individuals 60 years of age. Cardiotoxicity was higher in smokers (5.3 %), dyslipidemic patients (3.9 %), BMI ≥25 (6.5 %), diabetes (6.2 %), hypertension (5.5 %), or positive history of cardiac disease (19.1 %). RCTs consistently report lower cardiac toxicity rates than observational studies (EBC: 1.7 versus 3.2; MBC: 2.8 versus 4.4). Following trastuzumab initiation, approximately three in 100 patients develop severe cardiotoxicity after 2 years. Patients enrolled in cohort studies, who more closely reflect women treated for breast cancer in real-life settings compared to RCTs, are at higher risk of developing cardiac events.

Original languageEnglish
Pages (from-to)123-140
Number of pages18
JournalInternal and Emergency Medicine
Volume11
Issue number1
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Meta-Analysis
Cohort Studies
Breast Neoplasms
Taxoids
Therapeutics
Anthracyclines
Heart Diseases
Trastuzumab
Cardiotoxicity
MEDLINE
Libraries
Observational Studies
Clinical Trials
Hypertension
Survival

Keywords

  • Cardiotoxicity
  • Early breast cancer
  • Heart failure
  • Meta-analysis
  • Metastatic breast cancer
  • Trastuzumab

ASJC Scopus subject areas

  • Emergency Medicine
  • Internal Medicine

Cite this

Risk of severe cardiotoxicity following treatment with trastuzumab : a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. / Mantarro, Stefania; Rossi, Marta; Bonifazi, Martina; D’Amico, Roberto; Blandizzi, Corrado; La Vecchia, Carlo; Negri, Eva Vanna Lorenza; Moja, Pasquale Lorenzo.

In: Internal and Emergency Medicine, Vol. 11, No. 1, 01.02.2016, p. 123-140.

Research output: Contribution to journalArticle

Mantarro, Stefania ; Rossi, Marta ; Bonifazi, Martina ; D’Amico, Roberto ; Blandizzi, Corrado ; La Vecchia, Carlo ; Negri, Eva Vanna Lorenza ; Moja, Pasquale Lorenzo. / Risk of severe cardiotoxicity following treatment with trastuzumab : a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. In: Internal and Emergency Medicine. 2016 ; Vol. 11, No. 1. pp. 123-140.
@article{0f080dd3426a4f1c91edf51b82478ab6,
title = "Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer",
abstract = "Trastuzumab prolongs survival in women with HER2-positive breast cancer, but may increase the risk of heart disease. The occurrence of severe cardiotoxicity, however, is not defined in real-life settings. We performed a meta-analysis of clinical trials and cohort studies to estimate the frequency of cardiotoxicities following trastuzumab treatment. We searched MEDLINE, EMBASE, and the Cochrane Library (1996–January 2014). The primary outcome was the frequency of severe cardiotoxicities up to 3-years after trastuzumab initiation. Among 58 studies (29,598 patients), severe cardiotoxicity occurred in 3.00 {\%} (95 {\%} CI 2.41–3.64), 2.62 {\%} (95 {\%} CI 1.97–3.35), and 3.14 {\%} (95 {\%} CI 2.12–4.37) of overall, early (EBC) and metastatic (MBC) breast cancer patients, respectively. In EBC, the proportion increased from 2.40 {\%} at the first year to a plateau of approximately 3 {\%} after the second year. In MBC, the proportion increased from 3.00 to 3.68 {\%} when trastuzumab was used as first line or further lines of therapy, respectively. In EBC, cardiotoxicity occurred in 2.90 {\%} of patients treated with taxanes and anthracyclines compared to 0.92 {\%} in patients treated with taxanes without anthracyclines. The occurrence of cardiotoxicity varied according to age, increasing from 2.31 {\%} in individuals 60 years of age. Cardiotoxicity was higher in smokers (5.3 {\%}), dyslipidemic patients (3.9 {\%}), BMI ≥25 (6.5 {\%}), diabetes (6.2 {\%}), hypertension (5.5 {\%}), or positive history of cardiac disease (19.1 {\%}). RCTs consistently report lower cardiac toxicity rates than observational studies (EBC: 1.7 versus 3.2; MBC: 2.8 versus 4.4). Following trastuzumab initiation, approximately three in 100 patients develop severe cardiotoxicity after 2 years. Patients enrolled in cohort studies, who more closely reflect women treated for breast cancer in real-life settings compared to RCTs, are at higher risk of developing cardiac events.",
keywords = "Cardiotoxicity, Early breast cancer, Heart failure, Meta-analysis, Metastatic breast cancer, Trastuzumab",
author = "Stefania Mantarro and Marta Rossi and Martina Bonifazi and Roberto D’Amico and Corrado Blandizzi and {La Vecchia}, Carlo and Negri, {Eva Vanna Lorenza} and Moja, {Pasquale Lorenzo}",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s11739-015-1362-x",
language = "English",
volume = "11",
pages = "123--140",
journal = "Internal and Emergency Medicine",
issn = "1828-0447",
publisher = "Springer-Verlag Italia s.r.l.",
number = "1",

}

TY - JOUR

T1 - Risk of severe cardiotoxicity following treatment with trastuzumab

T2 - a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer

AU - Mantarro, Stefania

AU - Rossi, Marta

AU - Bonifazi, Martina

AU - D’Amico, Roberto

AU - Blandizzi, Corrado

AU - La Vecchia, Carlo

AU - Negri, Eva Vanna Lorenza

AU - Moja, Pasquale Lorenzo

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Trastuzumab prolongs survival in women with HER2-positive breast cancer, but may increase the risk of heart disease. The occurrence of severe cardiotoxicity, however, is not defined in real-life settings. We performed a meta-analysis of clinical trials and cohort studies to estimate the frequency of cardiotoxicities following trastuzumab treatment. We searched MEDLINE, EMBASE, and the Cochrane Library (1996–January 2014). The primary outcome was the frequency of severe cardiotoxicities up to 3-years after trastuzumab initiation. Among 58 studies (29,598 patients), severe cardiotoxicity occurred in 3.00 % (95 % CI 2.41–3.64), 2.62 % (95 % CI 1.97–3.35), and 3.14 % (95 % CI 2.12–4.37) of overall, early (EBC) and metastatic (MBC) breast cancer patients, respectively. In EBC, the proportion increased from 2.40 % at the first year to a plateau of approximately 3 % after the second year. In MBC, the proportion increased from 3.00 to 3.68 % when trastuzumab was used as first line or further lines of therapy, respectively. In EBC, cardiotoxicity occurred in 2.90 % of patients treated with taxanes and anthracyclines compared to 0.92 % in patients treated with taxanes without anthracyclines. The occurrence of cardiotoxicity varied according to age, increasing from 2.31 % in individuals 60 years of age. Cardiotoxicity was higher in smokers (5.3 %), dyslipidemic patients (3.9 %), BMI ≥25 (6.5 %), diabetes (6.2 %), hypertension (5.5 %), or positive history of cardiac disease (19.1 %). RCTs consistently report lower cardiac toxicity rates than observational studies (EBC: 1.7 versus 3.2; MBC: 2.8 versus 4.4). Following trastuzumab initiation, approximately three in 100 patients develop severe cardiotoxicity after 2 years. Patients enrolled in cohort studies, who more closely reflect women treated for breast cancer in real-life settings compared to RCTs, are at higher risk of developing cardiac events.

AB - Trastuzumab prolongs survival in women with HER2-positive breast cancer, but may increase the risk of heart disease. The occurrence of severe cardiotoxicity, however, is not defined in real-life settings. We performed a meta-analysis of clinical trials and cohort studies to estimate the frequency of cardiotoxicities following trastuzumab treatment. We searched MEDLINE, EMBASE, and the Cochrane Library (1996–January 2014). The primary outcome was the frequency of severe cardiotoxicities up to 3-years after trastuzumab initiation. Among 58 studies (29,598 patients), severe cardiotoxicity occurred in 3.00 % (95 % CI 2.41–3.64), 2.62 % (95 % CI 1.97–3.35), and 3.14 % (95 % CI 2.12–4.37) of overall, early (EBC) and metastatic (MBC) breast cancer patients, respectively. In EBC, the proportion increased from 2.40 % at the first year to a plateau of approximately 3 % after the second year. In MBC, the proportion increased from 3.00 to 3.68 % when trastuzumab was used as first line or further lines of therapy, respectively. In EBC, cardiotoxicity occurred in 2.90 % of patients treated with taxanes and anthracyclines compared to 0.92 % in patients treated with taxanes without anthracyclines. The occurrence of cardiotoxicity varied according to age, increasing from 2.31 % in individuals 60 years of age. Cardiotoxicity was higher in smokers (5.3 %), dyslipidemic patients (3.9 %), BMI ≥25 (6.5 %), diabetes (6.2 %), hypertension (5.5 %), or positive history of cardiac disease (19.1 %). RCTs consistently report lower cardiac toxicity rates than observational studies (EBC: 1.7 versus 3.2; MBC: 2.8 versus 4.4). Following trastuzumab initiation, approximately three in 100 patients develop severe cardiotoxicity after 2 years. Patients enrolled in cohort studies, who more closely reflect women treated for breast cancer in real-life settings compared to RCTs, are at higher risk of developing cardiac events.

KW - Cardiotoxicity

KW - Early breast cancer

KW - Heart failure

KW - Meta-analysis

KW - Metastatic breast cancer

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84958109484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958109484&partnerID=8YFLogxK

U2 - 10.1007/s11739-015-1362-x

DO - 10.1007/s11739-015-1362-x

M3 - Article

VL - 11

SP - 123

EP - 140

JO - Internal and Emergency Medicine

JF - Internal and Emergency Medicine

SN - 1828-0447

IS - 1

ER -